•  
  •  
 

Abstract

Introduction: Clozapine remains the gold-standard antipsychotic for treatment-resistant schizophrenia, but its use is hindered by rare but serious adverse effects, such as hematologic abnormalities and myocarditis.

Purpose: This study investigated the adverse impacts of clozapine on blood markers and electrocardiographic (ECG) findings among patients with schizophrenia, emphasizing in early detection of life-threatening complications.

Methods: All patients initiated on clozapine at a psychiatric hospital in Athens, Greece, between January 2022 and June 2024 were considered for inclusion. Thirty-one patients with complete clinical and laboratory data were monitored for hematological, biochemical, and ECG changes at baseline, days 5–10, and after 1–2 months. Parameters evaluated included white blood cell (WBC) counts, differential counts, C-reactive protein (CRP), hepatic enzymes, creatine phosphokinase (CPK), troponin, and ECG changes.

Results: Of the 31 patients, two (6.5%) developed clozapine-induced myocarditis within the first three weeks, confirmed by clinical symptoms, ECG abnormalities, and elevated troponin levels, necessitating immediate clozapine discontinuation. Four patients exhibited prolonged QTc, two overlapping with myocarditis cases. Eleven experienced elevated CRP, while eosinophilia and transient hepatic or muscular enzyme elevations were also common, especially during rapid titration phases; indicating inflammatory responses or mild organ involvement. No cases of agranulocytosis or severe eosinophilic complications occurred.

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

Share

COinS